drugset / Trial / NCT06041646
Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation in Schizophrenia or Bipolar Disorder
NaSingle-groupOpen-labelTreatment
Summary
This is an in-clinic, single arm, open-label study assessing tachyphylaxis, tolerance, and withdrawal following repeated doses of Igalmi in adult males and females with agitation associated with schizophrenia or bipolar disorder.
Timeline
- Start
- 2023-10-02
- Primary completion
- 2024-04-29
- Completion
- 2024-04-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dexmedetomidine | Other / unclassified | 90 ug | Other |
| Subject | Dexmedetomidine | Other / unclassified | 180 ug | Other |